It presents with clinical features similar to other demyelinating diseases such as multiple sclerosis (MS) and aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), yet MOGAD is increasingly recognized as a separate clinical entity with a distinct pathophysiology and clinical management [4]. The gene discussed is AQP4; the disease is neuromyelitis optica.